1. Home
  2. EXEL vs ALCYU Comparison

EXEL vs ALCYU Comparison

Compare EXEL & ALCYU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXEL
  • ALCYU
  • Stock Information
  • Founded
  • EXEL 1994
  • ALCYU N/A
  • Country
  • EXEL United States
  • ALCYU
  • Employees
  • EXEL N/A
  • ALCYU 3
  • Industry
  • EXEL Biotechnology: Biological Products (No Diagnostic Substances)
  • ALCYU
  • Sector
  • EXEL Health Care
  • ALCYU
  • Exchange
  • EXEL Nasdaq
  • ALCYU NYSE
  • Market Cap
  • EXEL 9.8B
  • ALCYU N/A
  • IPO Year
  • EXEL 2000
  • ALCYU N/A
  • Fundamental
  • Price
  • EXEL $38.44
  • ALCYU $11.38
  • Analyst Decision
  • EXEL Buy
  • ALCYU
  • Analyst Count
  • EXEL 18
  • ALCYU 0
  • Target Price
  • EXEL $37.59
  • ALCYU N/A
  • AVG Volume (30 Days)
  • EXEL 2.4M
  • ALCYU N/A
  • Earning Date
  • EXEL 05-09-2025
  • ALCYU N/A
  • Dividend Yield
  • EXEL N/A
  • ALCYU N/A
  • EPS Growth
  • EXEL 170.77
  • ALCYU N/A
  • EPS
  • EXEL 1.76
  • ALCYU N/A
  • Revenue
  • EXEL $2,168,701,000.00
  • ALCYU N/A
  • Revenue This Year
  • EXEL $5.78
  • ALCYU N/A
  • Revenue Next Year
  • EXEL $10.94
  • ALCYU N/A
  • P/E Ratio
  • EXEL $21.84
  • ALCYU N/A
  • Revenue Growth
  • EXEL 18.50
  • ALCYU N/A
  • 52 Week Low
  • EXEL $20.14
  • ALCYU N/A
  • 52 Week High
  • EXEL $40.02
  • ALCYU N/A
  • Technical
  • Relative Strength Index (RSI)
  • EXEL 63.11
  • ALCYU 22.11
  • Support Level
  • EXEL $35.34
  • ALCYU $11.31
  • Resistance Level
  • EXEL $37.67
  • ALCYU $12.38
  • Average True Range (ATR)
  • EXEL 1.25
  • ALCYU 0.08
  • MACD
  • EXEL 0.30
  • ALCYU -0.01
  • Stochastic Oscillator
  • EXEL 97.93
  • ALCYU 6.54

About EXEL Exelixis Inc.

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

About ALCYU ALCHEMY INVTS ACQUISITION CORP 1 UNIT 1 CL A COM & 1/2 WT

Alchemy Investments Acquisition Corp 1 is a blank check company.

Share on Social Networks: